CapsoVision, Inc.
CVHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. At a $371.9M market cap, CapsoVision, Inc. ranks as a small-cap company within healthcare. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Market Cap
$371.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.46
EPS (Fwd)
—
ROE
-335.1%
ROA
-132.5%
Cash
$9.1M
Total Debt
$687,000
Free CF
-$16.3M
52W Change
42.6%
Annual Financials
Cash vs Debt
Where CV stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CV finished 0.76% above its 150-day moving average ($6.62) and 4.71% above its 200-day moving average ($6.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CV overbought or oversold?
At the October 20, 2026 close, CV's RSI(14) was 49.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $9.1M in cash comfortably exceeding the $687K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$16.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -335.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $9.8M (2023) to $13.6M (2025), reflecting a 39% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CV.